Welcome to our dedicated page for Surmodics SEC filings (Ticker: SRDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Surmodics, Inc. (SRDX) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including Form 8-K current reports and other key documents. These filings offer detailed information on Surmodics’ medical device and in vitro diagnostics operations, corporate transactions, and regulatory events.
For Surmodics, recent Form 8-K filings have documented material events such as quarterly financial results, a cyber incident, and the acquisition of the company by an affiliate of GTCR LLC. One Form 8-K describes the discovery of a third-party cyber incident affecting certain information technology systems, the company’s containment and remediation efforts, and the role of its cyber insurance coverage. Other 8-K filings furnish press releases reporting quarterly revenue, segment performance in the Medical Device and In Vitro Diagnostics businesses, and updated fiscal year financial guidance.
A significant Form 8-K filed on November 19, 2025, details the completion of the merger between Surmodics and BCE Merger Sub, Inc., an affiliate of GTCR. This filing explains that Merger Sub merged with and into Surmodics, with Surmodics surviving as a wholly owned subsidiary of BCE Parent, LLC. It describes the cash consideration paid per share of common stock, the treatment of equity awards, repayment and termination of the company’s credit agreement and related interest rate swap, and the resulting change in control. The filing also outlines Surmodics’ notifications to Nasdaq, the request for a Form 25 to delist its common stock, and the intention to file a Form 15 to deregister the stock and suspend Exchange Act reporting obligations.
Additional filings address governance and leadership changes triggered by the merger, including the resignation of prior directors and officers and the appointment of new directors and executive officers in accordance with the merger agreement. These documents provide structured information on the company’s post-transaction corporate structure and governing documents, such as amended and restated articles of incorporation and bylaws.
On Stock Titan, Surmodics filings are updated as they are posted to EDGAR, and AI-powered summaries highlight the main points of lengthy documents. Users can quickly see what each filing covers, from financial condition and segment performance to cybersecurity events, merger completion steps, delisting notices, and changes in control. This makes it easier to understand how regulatory disclosures reflect Surmodics’ transition from a publicly traded issuer on Nasdaq to a privately held subsidiary of an affiliate of GTCR.
Surmodics, Inc. (SRDX) senior executive Charles W. Olson reported the automatic cash-out of his equity holdings in connection with the company’s merger with BCE Parent, LLC. At the merger’s effective time, each share of Surmodics common stock was cancelled and converted into the right to receive $43.00 per share in cash, and all of Olson’s restricted stock units vested and became entitled to the same cash consideration.
The filing shows that 51,478 shares of common stock held directly and 800 shares held through an IRA were disposed of, and multiple employee stock options with exercise prices between $33.64 and $56.63 covering various share amounts were cancelled. Each option was converted into a cash right equal to the number of underlying shares multiplied by the excess of the $43.00 merger consideration over the option’s exercise price. As a result of the merger, Olson no longer beneficially owns any Surmodics common stock.
Surmodics, Inc. (SRDX) completed a cash merger in which all common shares were converted into the right to receive $43.00 per share in cash. This Form 4 reports that the company’s VP Finance and Corporate Controller had all 8,155 shares of common stock disposed of in connection with the transaction.
Multiple employee stock options with exercise prices ranging from $33.64 to $43.93 covering 1,740, 1,862, 4,584, 4,810 and 3,160 underlying shares were cancelled at the effective time of the merger and converted into cash based on the excess of the $43.00 merger consideration over each option’s exercise price. Following these transactions, the reporting person no longer beneficially owns any Surmodics common stock.
Surmodics Inc. completed a merger in which all outstanding common stock was converted into cash at $43.00 per share. Under the merger agreement, Surmodics became a wholly owned subsidiary of BCE Parent, LLC after BCE Merger Sub, Inc. merged into the company.
The reporting person, a senior vice president and general counsel, had all restricted stock units vest immediately before the effective time and became entitled to receive the same $43.00 per share cash consideration for those RSUs. All employee stock options with exercise prices such as $36.23, $37.44, $43.93, $36.13 and $33.64 were cancelled and converted into a cash payment equal to the number of underlying shares multiplied by the excess of $43.00 over the option exercise price.
As a result of these transactions, the reporting person no longer beneficially owns any Surmodics common stock or related stock options.
Surmodics Inc. (SRDX)$43.00 per share in cash, subject to tax withholding. All restricted stock units held by the executive vested immediately before closing and will receive the same cash consideration.
The filing also shows that multiple employee stock options with exercise prices ranging from $33.64 to $56.63 were cancelled and converted into cash based on the excess of the $43.00 merger price over each option’s exercise price, if any. Following these transactions, the reporting person no longer beneficially owns any Surmodics common stock or related options.
Surmodics Inc. (SRDX) director reports full cash-out following merger. The filing describes the closing of a merger in which BCE Merger Sub, Inc. merged into Surmodics, Inc., making Surmodics a wholly owned subsidiary of BCE Parent, LLC. At the effective time, each share of Surmodics common stock was cancelled and converted into the right to receive $43.00 per share in cash, before taxes.
All restricted stock units held by the reporting person vested immediately before the merger and are entitled to the same $43.00 per-share cash consideration. The director disposed of 40,183 shares of common stock and multiple employee stock options covering several thousand shares at exercise prices ranging from $28.98 to $55.24, which were cancelled and converted into their in-the-money cash value. Following these transactions, the reporting person no longer beneficially owns any Surmodics common stock or stock options.
Surmodics, Inc. (SRDX)$43.00 per share in cash, subject to tax withholding. The filing shows that all restricted stock units held by this person vested immediately before the merger’s effective time and will be paid the same cash amount per share.
The director’s outstanding employee stock options, with exercise prices ranging from $28.98 to $55.24 and covering several option grants, were cancelled and converted into cash equal to the in-the-money value based on the $43.00 merger consideration. Following these transactions, the reporting person no longer beneficially owns any shares of Surmodics common stock.
Surmodics, Inc. (SRDX)
At the effective time of the merger, each share of Surmodics common stock was cancelled and converted into the right to receive $43.00 per share in cash, before taxes. All restricted stock units held by the reporting person vested immediately before closing and are entitled to the same $43.00 cash consideration per underlying share.
All reported employee stock options with exercise prices such as $55.24, $39.58, $53.86, $41.81, $28.98 and $31.89 were cancelled and converted into cash equal to the number of option shares multiplied by the excess of $43.00 over the option’s exercise price, subject to tax withholding. As a result of the merger, the reporting person no longer beneficially owns any Surmodics common stock.
Surmodics, Inc. (SRDX) filed a Form 4 showing that a director’s equity was cashed out in connection with the company’s merger. On 11/19/2025, all shares of Surmodics common stock held by the reporting person were cancelled and converted into the right to receive $43.00 per share in cash under a previously signed merger agreement with BCE Parent, LLC.
All restricted stock units held by the director vested immediately before the merger’s effective time and are also entitled to the $43.00 per-share cash consideration. In addition, multiple unexercised employee stock options with exercise prices ranging from $28.98 to $55.24 were cancelled and converted into cash equal to the spread between the $43.00 merger consideration and each option’s exercise price, subject to tax withholdings. Following these transactions, the reporting person no longer beneficially owns any Surmodics common stock.
Surmodics, Inc. (SRDX)$43.00 in cash per share, subject to tax withholdings.
All restricted stock units held by the reporting person vested immediately before the merger’s effective time and were also converted into the cash merger consideration. Multiple outstanding employee stock options with exercise prices ranging from $33.64 to $56.63 per share were cancelled and converted into cash equal to the number of shares underlying each option times the amount by which the $43.00 merger price exceeded the option’s exercise price. After these transactions, the reporting person holds no Surmodics common stock or derivative securities.
FAQ
What is the current stock price of Surmodics (SRDX)?
What is the market cap of Surmodics (SRDX)?
